Cargando…

Asprosin inhibits macrophage lipid accumulation and reduces atherosclerotic burden by up-regulating ABCA1 and ABCG1 expression via the p38/Elk-1 pathway

BACKGROUND: Asprosin, a newly discovered adipokine, is a C-terminal cleavage product of profibrillin. Asprosin has been reported to participate in lipid metabolism and cardiovascular disease, but its role in atherogenesis remains elusive. METHODS: Asprosin was overexpressed in THP-1 macrophage-deriv...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Jin, Xu, Can, Zhao, Zhen-Wang, Yin, Shan-Hui, Wang, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331044/
https://www.ncbi.nlm.nih.gov/pubmed/35902881
http://dx.doi.org/10.1186/s12967-022-03542-0
_version_ 1784758307526803456
author Zou, Jin
Xu, Can
Zhao, Zhen-Wang
Yin, Shan-Hui
Wang, Gang
author_facet Zou, Jin
Xu, Can
Zhao, Zhen-Wang
Yin, Shan-Hui
Wang, Gang
author_sort Zou, Jin
collection PubMed
description BACKGROUND: Asprosin, a newly discovered adipokine, is a C-terminal cleavage product of profibrillin. Asprosin has been reported to participate in lipid metabolism and cardiovascular disease, but its role in atherogenesis remains elusive. METHODS: Asprosin was overexpressed in THP-1 macrophage-derived foam cells and apoE(−/−) mice using the lentiviral vector. The expression of relevant molecules was determined by qRT-PCR and/or western blot. The intracellular lipid accumulation was evaluated by high-performance liquid chromatography and Oil red O staining. HE and Oil red O staining was employed to assess plaque burden in vivo. Reverse cholesterol transport (RCT) efficiency was measured using [(3)H]-labeled cholesterol. RESULTS: Exposure of THP-1 macrophages to oxidized low-density lipoprotein down-regulated asprosin expression. Lentivirus-mediated overexpression of asprosin promoted cholesterol efflux and inhibited lipid accumulation in THP-1 macrophage-derived foam cells. Mechanistic analysis revealed that asprosin overexpression activated p38 and stimulated the phosphorylation of ETS-like transcription factor (Elk-1) at Ser383, leading to Elk-1 nuclear translocation and the transcriptional activation of ATP binding cassette transporters A1 (ABCA1) and ABCG1. Injection of lentiviral vector expressing asprosin diminished atherosclerotic lesion area, increased plaque stability, improved plasma lipid profiles and facilitated RCT in apoE(−/−) mice. Asprosin overexpression also increased the phosphorylation of p38 and Elk-1 as well as up-regulated the expression of ABCA1 and ABCG1 in the aortas. CONCLUSION: Asprosin inhibits lipid accumulation in macrophages and decreases atherosclerotic burden in apoE(−/−) mice by up-regulating ABCA1 and ABCG1 expression via activation of the p38/Elk-1 signaling pathway. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03542-0.
format Online
Article
Text
id pubmed-9331044
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93310442022-07-29 Asprosin inhibits macrophage lipid accumulation and reduces atherosclerotic burden by up-regulating ABCA1 and ABCG1 expression via the p38/Elk-1 pathway Zou, Jin Xu, Can Zhao, Zhen-Wang Yin, Shan-Hui Wang, Gang J Transl Med Research BACKGROUND: Asprosin, a newly discovered adipokine, is a C-terminal cleavage product of profibrillin. Asprosin has been reported to participate in lipid metabolism and cardiovascular disease, but its role in atherogenesis remains elusive. METHODS: Asprosin was overexpressed in THP-1 macrophage-derived foam cells and apoE(−/−) mice using the lentiviral vector. The expression of relevant molecules was determined by qRT-PCR and/or western blot. The intracellular lipid accumulation was evaluated by high-performance liquid chromatography and Oil red O staining. HE and Oil red O staining was employed to assess plaque burden in vivo. Reverse cholesterol transport (RCT) efficiency was measured using [(3)H]-labeled cholesterol. RESULTS: Exposure of THP-1 macrophages to oxidized low-density lipoprotein down-regulated asprosin expression. Lentivirus-mediated overexpression of asprosin promoted cholesterol efflux and inhibited lipid accumulation in THP-1 macrophage-derived foam cells. Mechanistic analysis revealed that asprosin overexpression activated p38 and stimulated the phosphorylation of ETS-like transcription factor (Elk-1) at Ser383, leading to Elk-1 nuclear translocation and the transcriptional activation of ATP binding cassette transporters A1 (ABCA1) and ABCG1. Injection of lentiviral vector expressing asprosin diminished atherosclerotic lesion area, increased plaque stability, improved plasma lipid profiles and facilitated RCT in apoE(−/−) mice. Asprosin overexpression also increased the phosphorylation of p38 and Elk-1 as well as up-regulated the expression of ABCA1 and ABCG1 in the aortas. CONCLUSION: Asprosin inhibits lipid accumulation in macrophages and decreases atherosclerotic burden in apoE(−/−) mice by up-regulating ABCA1 and ABCG1 expression via activation of the p38/Elk-1 signaling pathway. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03542-0. BioMed Central 2022-07-28 /pmc/articles/PMC9331044/ /pubmed/35902881 http://dx.doi.org/10.1186/s12967-022-03542-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zou, Jin
Xu, Can
Zhao, Zhen-Wang
Yin, Shan-Hui
Wang, Gang
Asprosin inhibits macrophage lipid accumulation and reduces atherosclerotic burden by up-regulating ABCA1 and ABCG1 expression via the p38/Elk-1 pathway
title Asprosin inhibits macrophage lipid accumulation and reduces atherosclerotic burden by up-regulating ABCA1 and ABCG1 expression via the p38/Elk-1 pathway
title_full Asprosin inhibits macrophage lipid accumulation and reduces atherosclerotic burden by up-regulating ABCA1 and ABCG1 expression via the p38/Elk-1 pathway
title_fullStr Asprosin inhibits macrophage lipid accumulation and reduces atherosclerotic burden by up-regulating ABCA1 and ABCG1 expression via the p38/Elk-1 pathway
title_full_unstemmed Asprosin inhibits macrophage lipid accumulation and reduces atherosclerotic burden by up-regulating ABCA1 and ABCG1 expression via the p38/Elk-1 pathway
title_short Asprosin inhibits macrophage lipid accumulation and reduces atherosclerotic burden by up-regulating ABCA1 and ABCG1 expression via the p38/Elk-1 pathway
title_sort asprosin inhibits macrophage lipid accumulation and reduces atherosclerotic burden by up-regulating abca1 and abcg1 expression via the p38/elk-1 pathway
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331044/
https://www.ncbi.nlm.nih.gov/pubmed/35902881
http://dx.doi.org/10.1186/s12967-022-03542-0
work_keys_str_mv AT zoujin asprosininhibitsmacrophagelipidaccumulationandreducesatheroscleroticburdenbyupregulatingabca1andabcg1expressionviathep38elk1pathway
AT xucan asprosininhibitsmacrophagelipidaccumulationandreducesatheroscleroticburdenbyupregulatingabca1andabcg1expressionviathep38elk1pathway
AT zhaozhenwang asprosininhibitsmacrophagelipidaccumulationandreducesatheroscleroticburdenbyupregulatingabca1andabcg1expressionviathep38elk1pathway
AT yinshanhui asprosininhibitsmacrophagelipidaccumulationandreducesatheroscleroticburdenbyupregulatingabca1andabcg1expressionviathep38elk1pathway
AT wanggang asprosininhibitsmacrophagelipidaccumulationandreducesatheroscleroticburdenbyupregulatingabca1andabcg1expressionviathep38elk1pathway